Last updated: April 23, 2026
KHEDEZLA is an infliximab biosimilar with an FDA pathway tied to reference product infliximab. The investment case turns on launch adoption, payer acceptance, reimbursement durability, exclusivity and switching dynamics, safety and interchangeability signals, and the ability to defend share against both reference infliximab and other biosimilars in the same class.
What is KHEDEZLA and how is it positioned?
Product: KHEDEZLA (infliximab-dyyb)
Drug class: TNF-alpha inhibitor (monoclonal antibody biosimilar)
Therapeutic area: Autoimmune inflammatory diseases where originator infliximab is standard of care (for example, IBD and other TNF-mediated conditions).
Competitive set: Reference infliximab (Remicade) and infliximab biosimilars approved for the same indications.
Investment implication: KHEDEZLA competes primarily on price and access, with clinical differentiation constrained by biosimilar comparability requirements. The “fundamentals” therefore rely on commercial execution and portfolio protection rather than novel mechanism claims.
What are the key commercial fundamentals investors should underwrite?
1) Market access and net price
Biosimilar value is driven by net price after rebates and contracting rather than WAC. For infliximab, the market typically shifts through:
- Formulary inclusion decisions (hospital and payer)
- Infusion-center tendering and contracting
- Policy-driven switching programs
- Channel mix (hospital outpatient vs specialty pharmacy where applicable)
Investment read-through: A meaningful fraction of biosimilar revenue upside comes from managed entry (contracting wins, payer coverage, and provider switching protocols) rather than isolated prescription volume.
2) Uptake curve and persistence
Infliximab is a long-duration chronic therapy. Core investor questions:
- Does KHEDEZLA achieve early volume share in the high-prescribing centers that drive volume?
- Does it keep patients on therapy across cycles?
- Does it avoid “winner-takes-most” attrition when additional biosimilars or reference product promotions enter?
Investment read-through: Persistence matters as much as initial conversion. Switching programs can drive early adoption but also create re-switch risk if contract terms change.
3) Safety, interchangeability, and provider confidence
Biosimilar uptake depends on prescriber confidence in safety and efficacy equivalence. While the approval basis is comparability, the market often responds to:
- Post-approval pharmacovigilance visibility
- Interchangeability status (where applicable)
- Uptake guidance from institutions and professional communities
Investment read-through: Even small changes in formulary policy can shift share materially in a biologic infusion market.
What is the patent and exclusivity landscape that frames risk?
1) Patent protection is mostly about timing of exclusivity lapses
Biosimilars typically rely on expiration of reference product patents and exclusivity. Once biosimilar competition exists, the patent risk shifts toward:
- Patents on drug substance, formulation, manufacturing processes
- Device or dosing regimen claims (less common for biosimilars)
- Method-of-use patents that still have active term in specific indications
- Secondary patents and enforcement actions against commercial launch
Investment read-through: For a market entrant, the relevant question is whether any blocking patents exist beyond the approval date that can lead to launch delay, injunction risk, or commercial settlement restrictions.
2) Litigation and settlement dynamics
In biologics, market access can change after:
- Settlement terms (authorized launch dates, carve-outs, volumes)
- Court outcomes that affect commercialization scope
- Patent thickets that produce delayed exclusivity in sub-indications
Investment read-through: Investors should model scenario risk around injunctions or enforced switching limitations that directly impact market penetration.
How does KHEDEZLA fit into the infliximab biosimilar competitive field?
Competitive mechanics
Infliximab biosimilar competition tends to follow a repeatable pattern:
- First movers secure contracting momentum and institutional comfort
- Subsequent entrants fight for infusion center share and payer formulary positioning
- Price compression accelerates once multiple biosimilars are broadly contracted
Investment read-through: The biggest commercial hazard is net price erosion paired with slower conversion if contracting leaders already fill capacity and patient demand.
What valuation drivers matter most for an infliximab biosimilar business?
1) Unit economics anchored by net price and dose utilization
Key economic drivers:
- Effective net price (post rebates)
- Average treatment duration and patient persistence
- Utilization per site (patient volume and infusion capacity)
- Contracting terms (exclusivity, rebate ladders, throughput guarantees)
2) Supply, manufacturing scale, and cost of goods
Biosimilars require stable manufacturing at scale.
- Batch yields and release robustness affect unit cost
- Supply disruptions can cause missed cycles and lock loss to competitors
- Ramp-up costs impact margin early in commercialization
3) Operating leverage
Biosimilar revenue scales with:
- Commercial contracting success
- Reduced promotional intensity after early adoption
- Ongoing pharmacovigilance and tender operations
Investment read-through: The investment case is strongest when (a) the company reaches scale quickly and (b) net price stabilizes rather than sliding continuously.
Investment scenario framework (base, bull, bear)
Base case (most likely)
- KHEDEZLA gains incremental share through standard contracting and formulary inclusion.
- Net price compresses but stabilizes after early ramp.
- Growth tracks persistent patient conversion and retention.
- Patent and exclusivity risks do not create a material commercialization disruption.
Bull case
- Faster-than-market contracting wins in major infusion networks.
- Strong payer adoption and sustained switching programs.
- Net price erosion is less severe due to differentiated contracting terms.
- Patient persistence remains high, minimizing re-switch and churn.
Bear case
- Aggressive price competition compresses net price and slows margin recovery.
- Switching programs shift toward higher-volume competitors or reference product agreements.
- Any residual patent enforcement affects commercialization scope.
- Supply constraints trigger missed cycles and permanent share loss.
Key diligence checkpoints for investors
Focus diligence on the points that typically move realized revenue in biosimilar portfolios:
- Contracting coverage: percentage of target payers and infusion networks under contract and at what net price bands.
- Net price trajectory: WAC vs ASP vs contracted net price over time.
- Switching outcomes: conversion rates from originator and persistence on KHEDEZLA.
- Safety signal monitoring: pharmacovigilance trends and any emerging signal noise.
- Litigation posture: any injunction or settlement terms that constrain launch or indicate future enforcement risk.
- Manufacturing stability: batch release performance and supply continuity metrics during ramp.
Key Takeaways
- KHEDEZLA competes in a mature mechanism space where access and net price drive returns more than incremental clinical differentiation.
- The core investment upside is tied to contracting execution, switching conversion, and persistence in chronic infliximab treatment.
- The core investment downside is net price compression and any residual patent or litigation constraints that reduce commercialization scope or timing.
- Infliximab biosimilar investors should underwrite outcomes using scenario modeling on net price, persistence, and contracting coverage, with litigation and supply risk treated as gating items.
FAQs
1) What determines whether KHEDEZLA gains share in infliximab?
Formulary contracting, infusion-center tender outcomes, payer coverage and reimbursement terms, and patient switching persistence.
2) Why is net price more important than launch volume for infliximab biosimilars?
Because realized revenue is driven by rebates and contracting structure, which can vary materially from list price and can change as competitors enter or adjust pricing.
3) What is the main commercial risk after biosimilar launch?
Net price erosion and re-switch risk if contracts change or competing products secure preferential network status.
4) How does patent risk affect a biosimilar commercialization plan?
Patent enforcement can delay launch, restrict commercialization scope, or trigger settlement constraints that limit volume or market segments.
5) Which operational factor most influences margin in biologic biosimilars?
Manufacturing scale and release performance that support consistent supply while controlling cost of goods.
References
[1] U.S. Food and Drug Administration. Biosimilars information and regulatory framework (FDA.gov).
[2] U.S. Food and Drug Administration. Drugs@FDA database entry resources for biosimilars.
